These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 36427344

  • 1. Annual costs among patients with major depressive disorder and the impact of key clinical events.
    Cutler AJ, Keyloun KR, Higa S, Park J, Bonafede M, Gillard P, Jain R.
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
    [Abstract] [Full Text] [Related]

  • 2. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.
    Hidalgo-Mazzei D, Berk M, Cipriani A, Cleare AJ, Florio AD, Dietch D, Geddes JR, Goodwin GM, Grunze H, Hayes JF, Jones I, Kasper S, Macritchie K, McAllister-Williams RH, Morriss R, Nayrouz S, Pappa S, Soares JC, Smith DJ, Suppes T, Talbot P, Vieta E, Watson S, Yatham LN, Young AH, Stokes PRA.
    Br J Psychiatry; 2019 Jan; 214(1):27-35. PubMed ID: 30520709
    [Abstract] [Full Text] [Related]

  • 3. Ketamine: stimulating antidepressant treatment?
    Malhi GS, Byrow Y, Cassidy F, Cipriani A, Demyttenaere K, Frye MA, Gitlin M, Kennedy SH, Ketter TA, Lam RW, McShane R, Mitchell AJ, Ostacher MJ, Rizvi SJ, Thase ME, Tohen M.
    BJPsych Open; 2016 May; 2(3):e5-e9. PubMed ID: 27703782
    [Abstract] [Full Text] [Related]

  • 4. Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective.
    Schein J, Adler LA, Childress A, Gagnon-Sanschagrin P, Davidson M, Kinkead F, Cloutier M, Guérin A, Lefebvre P.
    J Manag Care Spec Pharm; 2022 Feb; 28(2):168-179. PubMed ID: 34806909
    [Abstract] [Full Text] [Related]

  • 5. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
    Schwedt TJ, Lee J, Knievel K, McVige J, Wang W, Wu Z, Gillard P, Shah D, Blumenfeld AM.
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
    [Abstract] [Full Text] [Related]

  • 6. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D, Rubin DT, Mease P, Mittal M, Liu H, Davis M, Ganguli A, Fendrick AM.
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [Abstract] [Full Text] [Related]

  • 7. Place of care and costs associated with acute episodes and remission in schizophrenia.
    McIntyre RS, Higa S, Doan QV, Amari DT, Mercer D, Gillard P, Harrington A.
    J Manag Care Spec Pharm; 2023 May; 29(5):499-508. PubMed ID: 37121252
    [Abstract] [Full Text] [Related]

  • 8. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
    Fendrick AM, Brixner D, Rubin DT, Mease P, Liu H, Davis M, Mittal M.
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
    [Abstract] [Full Text] [Related]

  • 9. The Emerging Role of Pimavanserin in the Management of Parkinson's Disease Psychosis.
    Hermanowicz N, Alva G, Pagan F, Espay AJ, Patel A, Madrid KC, Kremens D, Kenney J, Arquette S, Tereso G, Lopes M, Farnum C.
    J Manag Care Spec Pharm; 2017 Jun; 23(6-b Suppl):S2-S8. PubMed ID: 28636480
    [Abstract] [Full Text] [Related]

  • 10. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
    J Urol; 2023 Jul; 210(1):224-226. PubMed ID: 37119051
    [Abstract] [Full Text] [Related]

  • 11. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
    Smith MR, Sandhu S, George DJ, Chi KN, Saad F, Thiery-Vuillemin A, Stàhl O, Olmos D, Danila DC, Gafanov R, Castro E, Moon H, Joshua AM, Mason GE, Espina BM, Liu Y, Lopez-Gitlitz A, Francis P, Bevans KB, Fizazi K.
    J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
    [Abstract] [Full Text] [Related]

  • 12. Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine.
    Buse DC, Yugrakh MS, Lee LK, Bell J, Cohen JM, Lipton RB.
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1334-1343. PubMed ID: 32678721
    [Abstract] [Full Text] [Related]

  • 13. Effect of Headache-Free Days on Disability, Productivity, Quality of Life, and Costs Among Individuals with Migraine.
    Lipton RB, Lee L, Saikali NP, Bell J, Cohen JM.
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1344-1352. PubMed ID: 32678720
    [Abstract] [Full Text] [Related]

  • 14. CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.
    Newsome SD, Aliotta PJ, Bainbridge J, Bennett SE, Cutter G, Fenton K, Lublin F, Northrop D, Rintell D, Walker BD, Weigel M, Zackowski K, Jones DE.
    Int J MS Care; 2016 Oct; 18(6):314-323. PubMed ID: 27999526
    [Abstract] [Full Text] [Related]

  • 15. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
    Blauvelt A, Shi N, Zhu B, Burge R, Malatestinic WN, Lin CY, Lew CR, Zimmerman NM, Goldblum OM, Murage MJ.
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
    [Abstract] [Full Text] [Related]

  • 16. Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER).
    Ambrosini A, Estemalik E, Pascual J, Rettiganti M, Stroud C, Day K, Ford J.
    J Manag Care Spec Pharm; 2022 Jun; 28(6):645-656. PubMed ID: 35451858
    [Abstract] [Full Text] [Related]

  • 17. Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial.
    Holt RIG, Gossage-Worrall R, Hind D, Bradburn MJ, McCrone P, Morris T, Edwardson C, Barnard K, Carey ME, Davies MJ, Dickens CM, Doherty Y, Etherington A, French P, Gaughran F, Greenwood KE, Kalidindi S, Khunti K, Laugharne R, Pendlebury J, Rathod S, Saxon D, Shiers D, Siddiqi N, Swaby EA, Waller G, Wright S.
    Br J Psychiatry; 2019 Feb; 214(2):63-73. PubMed ID: 30251622
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Associations between childhood maltreatment and inflammatory markers.
    Palmos AB, Watson S, Hughes T, Finkelmeyer A, McAllister-Williams RH, Ferrier N, Anderson IM, Nair R, Young AH, Strawbridge R, Cleare AJ, Chung R, Frissa S, Goodwin L, Hotopf M, Hatch SL, Wang H, Collier DA, Thuret S, Breen G, Powell TR.
    BJPsych Open; 2019 Jan; 5(1):e3. PubMed ID: 30762500
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.
    Xing S, Batt K, Kuharic M, Bullano M, Caicedo J, Chakladar S, Markan R, Farahbakhshian S.
    J Manag Care Spec Pharm; 2023 Jun; 29(6):626-634. PubMed ID: 37276033
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.